Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 9OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 9Plasma cell 5Breast 5Thoracic 4Gastrointestinal 4Myeloid 3Genitourinary 3Dermatologic 3CNS 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Multiple Myeloma 5Recurrence 1Neoplasms 1Cytokine Release Syndrome 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × tocilizumab × Plasma cell × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT05391750 2026-02-17

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Emory University

Phase 1 Active not recruiting
7 enrolled
Plasma cell

Multiple Myeloma

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

University Health Network, Toronto

Phase 4 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT05855122 2023-06-02

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

The First Affiliated Hospital of Soochow University

Phase 4 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

NCT02447055 2016-07-12

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡